Non-Operative Options for Loco-regional Melanoma

Rebecca Knackstedt; Timothy Smile; Jennifer Yu; Brian R Gastman

doi:10.1016/j.cps.2021.05.007

Non-Operative Options for Loco-regional Melanoma

Clin Plast Surg. 2021 Oct;48(4):631-642. doi: 10.1016/j.cps.2021.05.007. Epub 2021 Jun 27.

Authors

Rebecca Knackstedt¹, Timothy Smile², Jennifer Yu², Brian R Gastman³

Affiliations

¹ Department of Plastic Surgery, Cleveland Clinic, 2049 East 100th Street, Desk A60, Cleveland, OH 44195, USA.
² Department of Radiation Oncology, Cleveland Clinic, Taussig Cancer Center, 10201 Carnegie Avenue, Cleveland, OH 44195, USA.
³ Department of Plastic Surgery, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, 2049 East 100th Street, Desk A60, Cleveland, OH 44195, USA. Electronic address: gastmab@ccf.org.

PMID: 34503723
DOI: 10.1016/j.cps.2021.05.007

Abstract

Malignant melanoma is the 5th most common cancer and stage IV melanoma accounts for approximately 4% of new melanoma diagnoses in the United States. The prognosis for regionally advanced disease is poor, but there have been numerous recent advances in the medical management of melanoma in-transit metastases. The goal of this paper is to review currently accepted treatment options for in-transit metastases and introduce emerging therapies. Therapies to be discussed include limb perfusion and infusion, immunotherapy, checkpoint inhibitors, and radiation therapy.

Keywords: Checkpoint inhibitors; Immunotherapy; Injectable therapy; Melanoma; Radiation therapy.

Publication types

Review

MeSH terms

Humans
Immunotherapy
Melanoma* / therapy
Skin Neoplasms* / therapy
United States